For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Heptares Therapeutics Limited

USPTO Granted Patents = 85

% Expired Patents = 1.2

EPO Patents = 29

Trademarks = 3

Forward Citations = 746

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Miles Stuart Congreve (60 out of 96 patents)

Benjamin Gerald Tehan (53 out of 60 patents)

Giles Albert Brown (50 out of 68 patents)

4. Mark Pickworth (34 out of 39 patents)

5. Julie Elaine Cansfield (25 out of 29 patents)

6. Barry John Teobald (19 out of 21 patents)

7. John Andrew Christopher (18 out of 24 patents)

8. Jonathan Stephen Mason (12 out of 16 patents)

9. Sarah Joanne Aves (10 out of 11 patents)

10. Mark David Rackham (8 out of 8 patents)

11. Sarah Joanne Bucknell (8 out of 13 patents)

12. Francesca Deflorian (8 out of 13 patents)

13. Christopher Gordon Tate (8 out of 10 patents)

14. Malcolm Peter Weir (8 out of 8 patents)

15. Michael Alistair O'Brien (8 out of 23 patents)

Core Competencies:

Muscarinic Agonists

Pharmaceutical Compounds

G-Protein Coupled Receptors

CGRP Receptor Antagonists

Bicyclic Aza Compounds

M1 Receptor Agonists

Stable Proteins

Inhibitors

Cyclohexapeptides

Orexin Receptor Antagonists

Substituted Cyclohexanes

Methods of Treatment

85 patents: Sort by Forward Citations

1. 12024499 - Muscarinic agonists (2024-07-02),

2. 11999745 - Pharmaceutical compounds (2024-06-04),

3. 11987648 - Cyclohexapeptides as selective somatostatin SST5 receptor agonists (2024-05-21),

4. 11945801 - Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists (2024-04-02),

5. 11834407 - Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists (2023-12-05),

6. 11793817 - Muscarinic M1 receptor agonists (2023-10-24),

7. 11773090 - Pharmaceutical compounds (2023-10-03),

8. 11680053 - Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (2023-06-20),

9. 11673938 - Mutant G-protein coupled receptors and methods for selecting them (2023-06-13),

10. 11584732 - Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (2023-02-21),

11. 11352342 - Pharmaceutical compounds (2022-06-07),

12. 11339383 - G proteins (2022-05-24),

13. 11324738 - Muscarinic agonists (2022-05-10),

14. 11319312 - Pharmaceutical compounds (2022-05-03),

15. 11254656 - Muscarinic agonists (2022-02-22),

Company Overview

Heptares Therapeutics Limited, based in Cambridge, UK, specializes in the development of innovative pharmaceutical compounds targeting muscarinic receptors. The company focuses on G-Protein Coupled Receptors (GPCRs), particularly muscarinic agonists and CGRP receptor antagonists, utilizing its proprietary technology to create stable proteins and bicyclic aza compounds. Heptares is dedicated to advancing therapies for various diseases by leveraging its expertise in receptor biology and drug design, aiming to address unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

85 Patents

#13 in Cambridge

#214 in United Kingdom

#8,962 in the World

Cambridge, United Kingdom

Heptares Therapeutics Limited

Forward Citations = 746

51 inventors:

Miles Stuart Congreve (60 out of 96 patents)

Benjamin Gerald Tehan (53 out of 60 patents)

Giles Albert Brown (50 out of 68 patents)

4. Mark Pickworth (34 out of 39 patents)

5. Julie Elaine Cansfield (25 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Heptares Therapeutics Limited. Retrieved from https://idiyas.com/company/heptares-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…